Paul Lorigan

63.1k total citations · 4 hit papers
330 papers, 12.8k citations indexed

About

Paul Lorigan is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Paul Lorigan has authored 330 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 256 papers in Oncology, 137 papers in Molecular Biology and 56 papers in Immunology. Recurrent topics in Paul Lorigan's work include Cancer Immunotherapy and Biomarkers (95 papers), Melanoma and MAPK Pathways (83 papers) and CAR-T cell therapy research (80 papers). Paul Lorigan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (95 papers), Melanoma and MAPK Pathways (83 papers) and CAR-T cell therapy research (80 papers). Paul Lorigan collaborates with scholars based in United Kingdom, United States and Germany. Paul Lorigan's co-authors include James Larkin, Caroline Robert, Antoni Ribas, Georgina V. Long, Jean‐Jacques Grob, Fiona Blackhall, Ana Arance, Omid Hamid, Mark R. Middleton and Matteo S. Carlino and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Paul Lorigan

321 papers receiving 12.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

2017 898 citations Georgina V. Long, Ana Arance et al. profile →
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

2019 768 citations Caroline Robert, Ana Arance et al. profile →
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

2016 397 citations Martin Reck, Alexander Luft et al. Journal of Clinical Oncology profile →
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

2017 354 citations Paul Lorigan et al. profile →

Peers

Countries citing papers authored by Paul Lorigan

Since Specialization

Citations

This map shows the geographic impact of Paul Lorigan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Lorigan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Lorigan more than expected).

Fields of papers citing papers by Paul Lorigan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Lorigan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Lorigan. The network helps show where Paul Lorigan may publish in the future.

Co-authorship network of co-authors of Paul Lorigan

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Lorigan. A scholar is included among the top collaborators of Paul Lorigan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Lorigan. Paul Lorigan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cancer diagnoses, referrals, and survival in people with a learning disability in the UK: a population-based, matched cohort study 2025 ·The Lancet Regional Health - Europe ·Oliver Kennedy, Umesh Chauhan, Louise Gorman, Paul Lorigan, Samuel WD Merriel, Tjeerd van Staa, Alison K. Wright, Darren M. Ashcroft	0
2	A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021 2025 ·British Journal of Dermatology ·(unknown), (unknown), N. J. Levell, Oliver Kennedy, Kathryn Richardson, Paul Craig, Chloe J. Bright, (unknown), (unknown), (unknown), Joanna Pethick, (unknown), Fiona E. McRonald, Steven J. Hardy, Sally Vernon, Paul Lorigan, Zoe C Venables	0
3	Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations 2025 ·PubMed ·(unknown), (unknown), Rebecca Lee, Paul Lorigan	0
4	Patterns of systemic treatment for melanoma: An insight on trends and costs between 2019–2023 from the English systemic anti-cancer therapy national database 2024 ·SHILAP Revista de lepidopterología ·(unknown), Oliver Kennedy, Rebecca Lee, Avinash Gupta, (unknown), (unknown), (unknown), (unknown), Paul Lorigan	1
5	Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN). 2024 ·Journal of Clinical Oncology ·Caroline Robert, Caroline Dutriaux, Felix Boakye Oppong, Michal Kiciński, Émilie Routier, Eve‐Marie Neidhardt, Xavier Durando, Barouyr Baroudjian, Philippe Saïag, Caroline Gaudy‐Marqueste, Paolo A. Ascierto, Ana Arance, Michelangelo Russillo, Jean‐Luc Perrot, Anne-Sophie Govaerts, (unknown), Bastian Schilling, Mario Mandalà, Paul Lorigan, Alexander Christopher Jonathan Van Akkooi	3
6	A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301). 2024 ·Journal of Clinical Oncology* ·Georgina V. Long, Victoria Atkinson, Paolo A. Ascierto, Diwakar Davar, Omid Hamid, Caroline Robert, Marcus O. Butler, Reinhard Dummer, Christine Häfner, Muhammad Adnan Khattak, James Larkin, Paul Lorigan, Meredith McKean, (unknown), Heather M. Shaw, Joe Stephenson, Yuan Yuan, (unknown), Piruntha Thiyagarajah, Dirk Schadendorf	3
7	COLUMBUS-AD: Phase III Study of Adjuvant Encorafenib + Binimetinib in Resected Stage IIB/IIC BRAF V600-Mutated Melanoma 2023 ·Future Oncology ·Alexander C. J. van Akkooi, Axel Hauschild, Georgina V. Long, Mario Mandalà, Michal Kiciński, Anne-Sophie Govaerts, (unknown), M. Ouali, Paul Lorigan, Alexander M.M. Eggermont	11
8	Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study 2022 ·European Journal of Cancer ·Patricio Serra-Bellver, Judith M. Versluis, (unknown), Cong Zhou, (unknown), Yasir Khan, James R. Patrinely, Inês Pires da Silva, Clara Martínez-Vila, Natalie Cook, Donna M. Graham, Matteo S. Carlino, Alexander M. Menzies, Ana Arance, Douglas B. Johnson, Georgina V. Long, Lisa Pickering, James Larkin, Christian U. Blank, Paul Lorigan	14
9	Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities 2022 ·European Journal of Cancer ·(unknown), Richard Heywood, (unknown), Patricio Serra-Bellver, Avinash Gupta, Tim Cooksley, Paul Lorigan	5
10	Cost‐effectiveness of a policy‐based intervention to reduce melanoma and other skin cancers associated with indoor tanning* 2022 ·British Journal of Dermatology ·Martin Eden, (unknown), Louisa G. Gordon, Tracy Epton, Paul Lorigan, Lesley E. Rhodes, Richard Marais, Adèle C. Green, Katherine Payne	13
11	SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study 2021 ·Journal for ImmunoTherapy of Cancer ·Mario Mandalà, Paul Lorigan, (unknown), (unknown), Barbara Merelli, Anna Bettini, Lucia Bonomi, (unknown), Maria Grazia Vitale, (unknown), (unknown), Paolo A. Ascierto, Eliana Rulli, Carlo Tondini	22
12	Sunbed Use among 11- to 17-Year-Olds and Estimated Number of Commercial Sunbeds in England with Implications for a ‘Buy-Back’ Scheme 2021 ·Children ·Louisa G. Gordon, (unknown), Martin Eden, Tracy Epton, Paul Lorigan, (unknown), Adèle C. Green, Katherine Payne	7
13	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer breakdown → 2016 ·Journal of Clinical Oncology ·Martin Reck, Alexander Luft, Aleksandra Szczęsna, Libor Havel, Sang-We Kim, Wallace Akerley, M. Catherine Pietanza, Yi‐Long Wu, Christoph Zielinski, Michael J. Thomas, Enriqueta Felip, Kathryn A. Gold, Leora Horn, Joachim G.J.V. Aerts, Kazuhiko Nakagawa, Paul Lorigan, Anne Pieters, (unknown), Justin Fairchild, David R. Spigel	397
14	Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery 2014 ·Cancer Research ·Andrew Hudson, Tim Yates, Yaoyong Li, Eleanor W. Trotter, Shameem Fawdar, (unknown), Paul Lorigan, Andrew V. Biankin, Crispin Miller, John Brognard	27
15	A meta-analysis of randomized, controlled trials in metastatic melanoma establishes progression-free survival as a surrogate for overall survival 2013 ·European Journal of Cancer ·Keith T. Flaherty, (unknown), Reinhard Dummer, Axel Hauschild, Michael Hennig, Guoxian Long, Paul Lorigan, (unknown), Dirk Schadendorf	1
16	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma 2012 ·Cancer Discovery ·María Romina Girotti, Malin Pedersen, Berta Sanchez‐Laorden, Amaya Virós, Samra Turajlic, Dan Niculescu‐Duvaz, Alfonso Zambon, John Sinclair, Andrew Hayes, Martin Gore, Paul Lorigan, Caroline J. Springer, James Larkin, Claus Jørgensen, Richard Marais	272
17	Safety and pharmacokinetics of first-line amg 479 (mab to igf1r) or amg 102 (mab to hgf/sf) with platinum-based chemotherapy in extensive-stage small cell lung cancer (sclc) 2010 ·Annals of Oncology ·Paul Lorigan, J.C. Soria, Joan Stephenson, (unknown), R. Gervais, (unknown), Ian McCaffery, (unknown), Jesse McGreivy, Bonnie S. Glisson	6
18	Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study 2007 ·Journal of Clinical Oncology ·Paul Lorigan, Jaap Verweij, Zsuzsa Pápai, Sjoerd Rodenhuis, Axel Le Cesne, Michael Leahy, John Radford, M. M. Van Glabbeke, Anne Kirkpatrick, Pancras C.W. Hogendoorn, Jean‐Yves Blay	192
19	Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial 2000 ·Annals of Oncology ·Axel Le Cesne, Ian Judson, John Radford, Jean‐Yves Blay, A. van Oosterom, Sjoerd Rodenhuis, Paul Lorigan, (unknown), José Jimeno, Jaco J. Verweij	9
20	Total CD34 yield and CFU-GM as mobolisation and subsequent engraftment after high dose chemotherapy. 1999 ·Research Explorer (The University of Manchester) ·Daniel Epurescu, (unknown), RJ Hinchliffe, Jennifer L. Peel, Daniel A. Jones, Elisabeth Vandenberghe, (unknown), Paul Lorigan	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact